Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors

作     者：Shi-Yong Sun Shi-Yong Sun

作者机构：Department of Hematology and Medical OncologyEmory University School of Medicine and Winship Cancer Institute of Emory UniversityAtlantaGA 30322USA 

出 版 物：《Chinese Medical Journal Pulmonary and Critical Care Medicine》 (呼吸与危重症医学（英文）)

年 卷 期：2023年第1卷第1期

页      面：3-10页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：I am thankful to Dr.Anthea Hammond in our department for editing the manuscript.Some of the work done in my lab was supported by the NIH/NCI R01 CA223220 R01 CA245386 UG1 CA233259 awards and Emory University Winship Cancer Institute lung cancer pilot funds 

主　　题：Lung cancer Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) Osimertinib Acquired resistance EGFR mutations 

摘      要：Although the clinical efficacies of third-generation epidermal growth factor receptor(EGFR)-tyrosine kinase in-hibitors(TKIs)such as osimertinib in the treatment of non-small cell lung cancer(NSCLC)with EGFR-activating mutations are promising,drug-acquired resistance inevitably occurs whether they are used as first-line or second-line ***,managing the acquired resistance to third-generation EGFR-TKIs is crucial in the clinic for improving patient *** efforts have been made to develop potentially effective strategies or regimens for the treatment of EGFR-mutant NSCLC patients after relapse following these TKIs therapies with the hope that patients will continue to benefit from treatment through overcoming acquired *** this approach,which aims to overcome drug-acquired resistance,is necessary and important,it is a passive *** pre-ventive action early before disease progression to manage the unavoidable development of acquired resistance offers an equally important and efficient *** strongly believe that early preventive interventions using effective and tolerable combination regimens that interfere with the process of developing acquired resistance may substantially improve the outcomes of EGFR-mutant NSCLC treatment with third-generation ***,this review focuses on discussing the scientific rationale and mechanism-driven strategies for delaying and even preventing the emergence of acquired resistance to third-generation EGFR-TKIs,particularly osimertinib.